“a clear trend”

Although there was a clear trend of an increased level of AQP4 in APP/PS1/eNOS +/− mice (22% increase; Figure 7 D,G), this difference was not statistically significant ( p = 0.087).

We found a clear trend towards a positive correlation between the T-ratios of drug responsiveness and the fold increase of CD40 levels post D + T treatment (Spearman r = 0.6571, p = 0.0875).

The difference was not statically significant for BMI 30 to <35 kg/m 2 , but a clear trend was noted (OR: 1.338; 95% CI: 0.957–1.871, p = 0.088).

However, there was a clear trend (p < 0.088) in the increase in total VFA content from 52.07 (control) to 56.78 mM and 69.44 mM in protein concentrate supplementation (extracted with distilled water) at 0.5% (IFW05) and 1.0% (IFW1) rations, respectively.

In multivariate analysis, a clear trend towards a potential role for telomerase activity as an independent prognostic factor of the TNM stage ( P = 0.089) and lymph node dissemination ( P = 0.101) was found.

However, a clear trend to decrease the TrkB level between the vehicle group and UCMS group was observed ( p = 0.0894, for Fig. 5 B).

However, a clear trend was observed in the THA group, in which the activity of this enzyme was 40% higher than in TNI animals (1.69 ± 0.21 vs. 2.35 ± 0.24, P = 0.09).

There was a clear trend towards lower CK-MB (p = 0.09), Troponin T (TnT) values (p = 0.06) and myocardial infarctions (p = 0.20) in the lidocaine treated group, but these did not reach statistical significance ( Table 1 ).

However, the interim analysis showed a clear trend towards improved primary endpoint outcomes in the ECMO group vs. the standard therapy group, with 65% vs. 54% 60-day survival, respectively ( p = 0.09).

Moreover, higher game based relaxation skills were associated with a clear trend in improvements in emotional control [ r (33) = 0.22, p = 0.09] and situation responsiveness [ r (33) = −0.25, p = 0.06], measured by ERICA.

Survival analysis in the validation group (n = 365) showed a clear trend towards better prognosis in GG homozygotes of the rs10757278 SNP, which confirms our initial results (p = 0.09, log-rank test).

Importantly, this resulted in a clear trend towards lowered overall NAFLD activity ( Figure 2 F, P = 0.09).

However, among 5–9 year old children with a serum PG I level >30 μg/L, there was a clear trend towards a higher rate of vibriocidal seroconversion (P = 0.09) ( Table 2 ).

After adjusting for age, the differences became less significant, but there was still a clear trend (OR 1.42; 95% CI 0.94–2.13, P = 0.09 and OR 1.42; 95% CI 0.96–2.09; P = 0.07, respectively).

In addition, when focussing only on the edema scores, a clear trend (p = 0.09) towards reduced scores for allopurinol pre-treated animals was found.

Compared with mouse IgG treatment, immunization with monoclonal antibody 43D showed a clear trend ( P = 0.09) to decrease the number of AT8 intensely stained neurons in the contralateral hippocampus, though it did not reach statistical significance (Fig. 4a and b ).

Because a clear trend was detected for an interaction between secretor status and Lewis phenotype ( P = .09) when tested by logistic regression, we stratified Le + vs Le – phenotype by secretor status ( Table 4 ).

Changes in CTC-cluster counts from baseline to follow up were not able to predict patient outcome in terms of PFS and OS, however, for patients in the high risk group, there was a clear trend towards a shorter OS ( P log-rank = 0.07) and increased risk of death, with a HR of 2.96 (95% CI 0.83–10.5; p = 0.09) ( Figure 4 , Table 4 ). 2.6.

Interestingly, nonhypertensive patients were not protected (OR 0.75, 95% CI, 0.46–1.30, P =0.26), nor were those with a history of MI despite the presence of a clear trend (OR 0.61, 95% CI, 0.35–1.09, P =0.09) (Figure 2 A).

Notably, the group with a Type 3 TIL profile displaying elevated CD3+ TILs and high lymphocyte GZB and/or Ki-67 showed a clear trend toward better survival in this population ( P = 0.09, log-rank test, Fig. 5d ).

Although not statistically significant, we also detected a clear trend towards lower plasma IL-6 levels in the ET group compared to non-HT group (p = 0.09).

However, a clear trend toward superior, sustained benefit was observed in the DFPP group at T2 (ΔMG‐ADL: 4.00 ± 2.98 vs. 1.93 ± 3.47, p = 0.091; β = −2.07, p = 0.068), suggesting more sustained clinical benefits (Figure 2B ). 3.3.

These ML B2/PNI− tumors had a significantly worse disease-specific survival (DSS, HR = 2.288, p = 3.8 × 10 −2 ) and showed a clear trend towards unfavorable overall survival (OS, HR = 1.711, p = 9.1 × 10 −2 ) and progression-free interval (PFI, HR = 1.669, p = 1.1 × 10 −1 ) compared to ML A/PNI− tumors ( Figure 3 D).

However, there was a clear trend to reduce death secondary to CV causes (HR 0.88 (95% CI: 0.76‒1.02, p = 0.092), that would be more evident if the follow-up times had been longer ( 95 ).

When analyzing the cell somata, a clear trend towards a reduced soma size was noted in irradiated neurons 0.5 h (0.1 Gy: p = 0.093, 1.0 Gy: p = 0.053) and 2 h (0.1 Gy: p = 0.021, 1.0 Gy: p = 0.085) as compared to non-irradiated neurons, which recovered after 24 h ( Fig 2C ).